Gennova Gets DCGI Nod To Conduct Phase 2,3 Trials Of Its MRNA COVID-19 Vaccine

Retrieved on: 2021-08-24 12:22:30

Tags for this article:

Clinical trials

RNA vaccines

Oxford–AstraZeneca COVID-19 vaccine

Deployment of COVID-19 vaccines

India

Gennova Biopharmaceuticals Ltd

Click the tags to see associated articles and topics

Gennova Gets DCGI Nod To Conduct Phase 2,3 Trials Of Its MRNA COVID-19 Vaccine. View article details on hiswai:

Excerpt

Gennova Biopharmaceuticals, the Pune-based biotechnology company which is developing India's first mRNA-based COVID-19 vaccine HGCO19, on August 24 received ...

Article found on: www.moneycontrol.com

View Original Article